A carregar...
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in regards to its interaction with ATP-bind...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7017082/ https://ncbi.nlm.nih.gov/pubmed/31940916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010186 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|